Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Zhu, Hai Bin ^a   Yang, Kai ^a   Xie, Yan Qi ^a   Lin, Yi Wei ^a   Mao, Qi Qi ^a   Xie, Li Ping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Bladder cancer; Cisplatin; Mutant p53; RNA interference

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; FLOW CYTOMETRY; GENE SILENCING; HUMANS; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84872811756     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-22     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866. 10.1056/NEJMoa022148, 12944571.
3. Splinter TA, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, Soloway M, Vogelzang NJ, van Tinteren H, Herr H, European Organization for Research on Treatment of Cancer-Genitourinary Group The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 1992, 147:606-608. European Organization for Research on Treatment of Cancer-Genitourinary Group.
4. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of Urology (EAU) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011, 59:1009-1018. 10.1016/j.eururo.2011.03.023, 21454009, European Association of Urology (EAU).
5. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130. 10.1038/nature07986, 2814168, 19407794.
6. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431. 10.1016/j.cell.2009.04.037, 19410540.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253:49-53. 10.1126/science.1905840, 1905840.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
9. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003, 100:8424-8429. 10.1073/pnas.1431692100, 166245, 12826609.
10. Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 1991, 11:12-19. 359578, 1986215.
11. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991, 65:65-74. 10.1016/0092-8674(91)90408-Q, 1826463.
12. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010, 2:a001107. 10.1101/cshperspect.a001107, 2828285, 20182618.
13. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006, 25:304-309.
14. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G, Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008, 7:1870-1879. 10.4161/cc.7.12.6161, 18594199.
15. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 2006, 24:5552-5564. 10.1200/JCO.2006.08.2073, 17158541.
16. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63:8108-8112.
17. Nishiyama H, Watanabe J, Ogawa O. p53 and chemosensitivity in bladder cancer. Int J Clin Oncol 2008, 13:282-286. 10.1007/s10147-008-0815-x, 18704627.
18. Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, Hatzivassiliou G, Tan J. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994, 6:569-579.
19. Riegerl KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA, Summerhayes IC. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 1995, 72:683-690. 10.1038/bjc.1995.394, 2033904, 7669581.
20. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene 2007, 26:2202-2211. 10.1038/sj.onc.1210294, 17401429.
21. Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic approaches in exploring gain of function of mutant p53. Curr Genomics 2008, 9:200-207. 10.2174/138920208784340713, 2679646, 19440517.
22. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485. 10.1038/sj.onc.1202314, 9927204.
23. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998, 16:3269-3277. 10.1038/sj.onc.1201867, 9681825.
24. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402. 10.1016/S1535-6108(03)00079-5, 12726864.
25. Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 1984, 38:119-126. 10.1016/0092-8674(84)90532-4, 6088057.
26. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2:711-719. 10.1038/nchembio839, 17108989.
27. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433. 10.1038/nature07758, 2702667, 19158789.
28. Ma LL, Sun WJ, Wang Z, Zh GY, Li P, Fu SB. Effects of silencing of mutant p53 gene in human lung adenocarcinoma cell line Anip973. J Exp Clin Cancer Res 2006, 25:585-592.
29. Zhu H, Mao Q, Lin Y, Yang K, Xie L. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells. Med Oncol 2011, 28(Suppl 1):S381-S387.
30. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nature Rev Cancer 2006, 6:99-106.
31. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007, 35:2093-2104. 10.1093/nar/gkm099, 1874625, 17344317.
32. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992, 11:961-971. 556537, 1312467.
33. Furuno N, den Elzen N, Pines J. Human cyclin A is required for mitosis until mid prophase. J Cell Biol 1999, 147:295-306. 10.1083/jcb.147.2.295, 2174228, 10525536.
34. Salvesen GS, Dixit VM. Caspase activation: the induced proximity model. Proc Natl Acad Sci USA 1999, 96:10964-10967. 10.1073/pnas.96.20.10964, 34227, 10500109.
35. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG. Cleavage of automodified poly (ADP-ribose) polymerase during apoptosis: evidence for involvement of caspase-7. J Biol Chem 1999, 274:28379-28384. 10.1074/jbc.274.40.28379, 10497198.
36. Lehmann J, Retz M, Stockle M. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World J Urol 2002, 20:144-150.
37. Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005, 92:645-650. 10.1038/sj.bjc.6602378, 2361881, 15685232.
38. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urology 2005, 174:14-20.
39. Theodore C, Geoffrois L, Vermorken JB, Caponigro F, Fiedler W, Chollet P, Ravaud A, Peters GJ, de Balincourt C, Lacombe D, Fumoleau P. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005, 41:1150-1157. 10.1016/j.ejca.2005.02.015, 15911238.
40. Perabo FG, Muller SC. New agents for treatment of advanced transitional cell carcinoma. Ann Oncol 2007, 18:835-843. 10.1093/annonc/mdl331, 17018703.
41. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23. 10.1016/j.ctrv.2006.09.006, 1855222, 17084534.
42. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
43. Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003, 23:633-655. 10.1002/med.10038, 12789689.
44. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. P53 and treatment of bladder cancer. Nature 1997, 385:123-124.
45. Watanabe J, Nishiyama H, Okubo K, Takahashi T, Toda Y, Habuchi T, Kakehi Y, Tada M, Ogawa O. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004, 63:989-993. 10.1016/j.urology.2003.11.031, 15135005.
46. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009, 14:597-606. 10.1007/s10495-009-0330-1, 19259822.
47. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992, 255:459-462. 10.1126/science.1346476, 1346476.
48. Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002, 98:323-330. 10.1002/ijc.10226, 11920581.